All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

lacidipine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
calcium channel blockers, nifedipine derivatives	1532	103890-78-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lacidipine lacipil lacirex GR-43659X motens	Molecular weight: 455.55 Formula: C26H33NO6 CLOGP: 5.93 LIPINSKI: 1 HAC: 7 HDO: 1 TPSA: 90.93 ALOGS: -5.31 ROTB: 11

Drug dosage:

Dose	Unit	Route
4	mg	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	18 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PRKDC,STK33,TEK,TTK,ZAP70	40
kinase-selectivity-class	AXL,BRAF,GRK2,PDK4,PIK3CD,STK33	6
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lower urinary tract symptoms	54.36	35.20	7	865	107	90627468

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Procalcitonin abnormal	70.33	30.82	12	1353	383	42619587
Encephalomalacia	58.49	30.82	12	1353	1049	42618921
Lymphocyte count increased	56.42	30.82	15	1350	4049	42615921
PO2 decreased	53.28	30.82	12	1353	1629	42618341
PCO2 decreased	52.21	30.82	12	1353	1782	42618188
Acquired macroglossia	46.26	30.82	6	1359	25	42619945
Device related sepsis	43.00	30.82	12	1353	3875	42616095
Monocyte count increased	38.47	30.82	12	1353	5682	42614288
Drug interaction	35.44	30.82	43	1322	266956	42353014
Procedural haemorrhage	32.47	30.82	9	1356	2832	42617138

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Procalcitonin abnormal	75.42	26.16	12	2220	397	110586670
Encephalomalacia	59.84	26.16	12	2220	1490	110585577
Lymphocyte count increased	59.42	26.16	16	2216	7187	110579880
PO2 decreased	50.99	26.16	12	2220	3136	110583931
PCO2 decreased	50.94	26.16	12	2220	3149	110583918
Drug interaction	48.79	26.16	55	2177	500128	110086939
International normalised ratio increased	48.75	26.16	27	2205	86745	110500322
Device related sepsis	40.43	26.16	12	2220	7635	110579432
Lower urinary tract symptoms	38.73	26.16	7	2225	499	110586568
Acquired macroglossia	36.08	26.16	6	2226	262	110586805
Scrotal oedema	35.75	26.16	8	2224	1673	110585394
Monocyte count increased	33.91	26.16	12	2220	13281	110573786
Procedural haemorrhage	30.81	26.16	9	2223	5418	110581649
Attention deficit hyperactivity disorder	27.95	26.16	8	2224	4483	110582584
Melaena	27.04	26.16	17	2215	68740	110518327
Splenomegaly	26.80	26.16	12	2220	24486	110562581

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C08CA09	CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives
MeSH PA	D000077264	Calcium-Regulating Hormones and Agents
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002121	Calcium Channel Blockers
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D049990	Membrane Transport Modulators
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35674	antihypertensive agent

Related Drugs by ATC class:

C08CA Dihydropyridine derivatives 17 drugs

amlodipinebarnidipinebenidipinecelecoxibcilnidipineclevidipinefelodipineisradipinelercanidipinelevamlodipinemanidipinenicardipine show all 17 →

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.23	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Voltage-gated L-type calcium channel	Ion channel	Q01668 Q13936	CAC1D_HUMAN CAC1C_HUMAN	BLOCKER				SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.25		DRUG MATRIX
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	5.68		DRUG MATRIX
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	5.64		DRUG MATRIX
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		IC50	6.05		DRUG MATRIX
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	5.70		DRUG MATRIX
Thromboxane-A synthase	Enzyme	P24557	THAS_HUMAN		IC50	5.77		DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	5.70		DRUG MATRIX
Androgen receptor	Transcription factor		ANDR_RAT		Ki	5.58		DRUG MATRIX

External reference:

ID	Source
4025250	VUID
N0000179165	NUI
D04657	KEGG_DRUG
4025250	VANDF
C0064568	UMLSCUI
CHEBI:135737	CHEBI
CHEMBL460291	ChEMBL_ID
DB09236	DRUGBANK_ID
C060285	MESH_SUPPLEMENTAL_RECORD_UI
11740	IUPHAR_LIGAND_ID
6093	INN_ID
260080034N	UNII
5311217	PUBCHEM_CID
28382	RXNORM
004453	NDDF
319299000	SNOMEDCT_US
395764001	SNOMEDCT_US

Pharmaceutical products:

None